Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19923130 | 0.85 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2FPR2 | |
| SCHEMBL1974742 | 0.82 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL642956 | 0.81 | SMN1; SMN2 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL14666113 | 0.79 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1ACHE | |
| SCHEMBL1463215 | 0.78 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1ACHE | |
| SCHEMBL10106379 | 0.77 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL18119744 | 0.73 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL13558667 | 0.73 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL4263862 | 0.73 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL9636527 | 0.72 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | NPC1 1540/4885RAB9A 2150/4885SMN1; SMN2 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.